Stefan Weigand

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi request reprint Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist
    Stefan Weigand
    Bayer Health Care AG, Pharma Research, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4619-23. 2005
  2. doi request reprint Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist
    Stefan Weigand
    Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
    Cancer Res 72:4329-39. 2012
  3. ncbi request reprint Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4201-5. 2005
  4. ncbi request reprint Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, Aprather Weg 18a, 42096 Wuppertal, Germany
    ChemMedChem 1:96-105. 2006

Collaborators

  • Christoph Schaab
  • Kentaro Hashimoto
  • Michael Brands
  • Stephan Siegel
  • Dirk Heimbach
  • Jens Kerim Ergüden
  • Johannes Peter Stasch
  • Christian Schröder
  • Hideki Tsujishita
  • Nagahiro H Yoshida
  • Thomas Krahn

Detail Information

Publications4

  1. ncbi request reprint Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist
    Stefan Weigand
    Bayer Health Care AG, Pharma Research, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4619-23. 2005
    ..Compound 33 showed good pharmacokinetics...
  2. doi request reprint Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist
    Stefan Weigand
    Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
    Cancer Res 72:4329-39. 2012
    ..Taken together, our approach augments the value of other high throughput techniques to identify biomarkers for clinical development of targeted agents...
  3. ncbi request reprint Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4201-5. 2005
    ..We report systematic optimization of this compound class by means of classical and solid-phase chemistry. Optimized compounds with a bisarylamide side chain at the 2-position of the indole skeleton exhibit low-nanomolar activity on ECE...
  4. ncbi request reprint Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, Aprather Weg 18a, 42096 Wuppertal, Germany
    ChemMedChem 1:96-105. 2006
    ..All ECE inhibitors of the indole class showed high selectivity for ECE over related metalloproteases such as NEP and ACE. Therefore, these compounds might have further potential as drugs for the treatment of coronary heart diseases...